Respiratory drugs highlighted in PBS costs report


Fixed dose combination inhalers for COPD have been flagged as high growth prescription items for the Pharmaceutical Benefits Scheme. In its annual expenditure report, the PBS highlights the LABA/LAMA combo tiotropium/olodaterol (Spiolto Respimat) as one of the products with the highest growth in prescription volume, with numbers increasing by 760% from 9,985 to 85,840 scripts ...


Already a member? Login to keep reading


OR
© 2018 the limbic